Full text is available at the source.
Abstract
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduces body weight, waist circumference, and haemoglobin A1c (HbA1c) levels in patients with schizophrenia.
- Randomised controlled trials have shown significant reductions in body weight among patients treated with GLP-1RAs.
- There is a noted decrease in waist circumference in patients receiving GLP-1RA treatment.
- Haemoglobin A1c (HbA1c) levels are also reduced with GLP-1RA therapy in this patient population.
- The applicability of these findings to real-world clinical settings remains uncertain due to participant selection in trials.
Simplified